SBIR/STTR Research Award

Phase-transition Hydrogel Microneedle

Award identifier d4e51e712724f2e182327c41a1b236d19c72e1be7f4230311bb6a22abce4b2bfAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$250,445

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BioPharm Solutions Inc
Proposal award date
2015-06-01
Contract end date
2016-05-31
UEI
Not reported
Solicitation number
PA14-071
Topic code
200

Research abstract

DESCRIPTION provided by applicant Non invasive delivery of protein and peptide drugs that require frequent administration such as insulin is a still standing challenge despite extensive research efforts over the last years We have recently developed a unique microneedle system the phase transition microneedle patch PTM which has proven to be a feasible dosage form by pharmacokinetic and efficacy studies using healthy and diabetic pig models PTM releases its cargo in the skin interstitial fluid by swelling instead of dissolution o its needle tips for which skin deposition of the polymeric materials as seen in dissolvable microneedles is avoided The water insoluble microneedles of PTM are comprised of a chemically inert pharmaceutical excipient polyvinyl alcohol PVA formed by a freeze thaw induced formation of microcrystalline domains as the cross linking junctions of the needle tip matrix Proteins and peptides can therefore be safely loaded in microneedle tips without being denatured by the cross linking reactions as is true of the chemically cross linked hydrogel forming microneedles The ultimate goal of the proposed study is to develop a practical insulin microneedle patch to control the basal blood sugar levels in diabetic patients without pain sensation or skin damage The specific aims of this study are optimization of the polymer components and fabrication process of PTM to achieve a steady sustained release of insulin for daily administration and obtaining pharmacokinetic parameters of the insulin PTM patch in pig models The animal experiment will be carried out at Rutgers University New Jersey Medical Schools the collaborator animal facility according to the institutional guidance for using vertebrate animals PUBLIC HEALTH RELEVANCE Despite decades of research efforts to develop an alternative delivery solution insulin an essential medicine for managing diabetes is typically administered to patients by frequent injections Our newly developed insulin skin patch delivery system called phase transition microneedle PTM patch circumvents any pain sensation or skin damage by utilizing an array of polymer microneedles pre loaded with insulin that absorb fluid from the skin to swell and accurately and efficiently deliver insulin therapy transdermally The present study is aimed to develop and characterize this preliminary invention into a medicinal patch to replace daily insulin injections for controlling the basal blood sugar of diabetic patients

Technology keywords

Not reported

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.